Cambridge, MA, United States of America

Mitchell Kopacz

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Factor Bioscience Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mitchell Kopacz. Retrieved from https://idiyas.com/inventor/mitchell-kopacz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mitchell Kopacz and His Work in Gene Editing

Introduction

Mitchell Kopacz is an inventor based in Cambridge, Massachusetts. His work includes a patent titled “Engineered Gene-Editing Proteins,” and he is associated with Factor Bioscience Inc. His patent record includes 1 patent.

Latest Patents

Kopacz is named on “Engineered Gene-Editing Proteins,” an invention concerning engineered proteins for gene-editing applications. The available information does not specify the patent’s filing or grant date.

Career Highlights

Kopacz’s listed patent connects his inventive work with Factor Bioscience Inc., a biotechnology company. The patent title reflects a focus on engineered tools for gene editing.

Collaborations

Kopacz’s listed coworkers include Franklin Kostas and Matthew Angel. Their names are associated with his professional context, though the available information does not specify their roles in the patent.

Conclusion

Mitchell Kopacz is a Cambridge-based inventor associated with Factor Bioscience Inc. and the patent “Engineered Gene-Editing Proteins,” reflecting his connection to gene-editing innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…